Endpoints shares our FDA letter

Adding to the list of larger news outlets covering what APC is up to is Endpoints News (from the Financial Times). It wrote about our letter to the FDA that pointed out that semaglutide isn’t difficult to compound, despite erroneous claims by Novo Nordisk.

In a piece on the battle between Eli Lilly and compounding pharmacists over tirzepatide — notably...

The story this past Monday is one of the best media reports on compounding that we’ve seen. The...

Fierce Pharma has another one of the type of articles we've been seeing a lot of — one that looks...

Endpoints shares our FDA letter

Related posts

Quartz mentions APC

Joe Navarra on NBC Nightly News

Another look at compounded post-shortage